United Therapeutics sells treatments for pulmonary hypertension and grows transplant organs.
United Therapeutics Corporation (UTHR) is expected to report earnings on Wednesday, November 4, 2026, before the open. Estimated release time 06:33 ET. Consensus EPS estimate is $6.21.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-08-05 | Jun 2026 qtr | $6.86 | $7.27 | +6.0% | $783.30M |
| 2026-05-06 | Mar 2026 qtr | $7.00 | $5.82 | — | $781.50M |
| 2026-02-25 | Dec 2025 qtr | $7.13 | $7.70 | +8.0% | $790.20M |
| 2025-10-29 | Sep 2025 qtr | $6.89 | $7.16 | +3.9% | $799.50M |
| 2025-07-30 | Jun 2025 qtr | $7.29 | $6.41 | -12.1% | $798.60M |
| 2025-04-30 | Mar 2025 qtr | $6.29 | $6.63 | +5.4% | $794.40M |
| 2025-02-26 | Dec 2024 qtr | $6.40 | $6.19 | -3.3% | $735.90M |
| 2024-10-30 | Sep 2024 qtr | $6.43 | $6.39 | -0.6% | $748.90M |
UTHR has beaten consensus EPS in 4 of its last 7 scored quarters.
See UTHR on the live calendar →